Acute On Chronic Liver Failure (ACLF) Global Market Report 2025

The acute on chronic liver failure (ACLF) market size has grown strongly in recent years. It will grow from $2.68 billion in 2024 to $2.89 billion in 2025 at a compound annual growth rate (CAGR) of 8%. The growth observed during the historic period can be linked to factors such as the increasing prevalence of chronic liver diseases, heightened awareness about liver health, growing healthcare spending, the development of new therapies, the rising incidence of alcohol-related liver damage, an increase in organ transplant procedures, advancements in critical care, a growing aging population, and expanded research into the mechanisms of liver failure.

The acute on chronic liver failure (ACLF) market size is expected to see strong growth in the next few years. It will grow to $3.89 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The anticipated growth during the forecast period can be attributed to the increasing adoption of liver support devices, advancements in regenerative medicine, a growing emphasis on precision medicine, rising demand for minimally invasive treatments, the development of targeted therapies, the expansion of healthcare infrastructure in emerging markets, increased investment in research and development, the rising prevalence of metabolic disorders, and the strengthening of public-private partnerships. Key trends expected in this period include the integration of artificial intelligence in diagnostics, the development of bioengineered liver tissue, advancements in extracorporeal liver support devices, the use of machine learning for personalized treatment plans, the emergence of gene editing technologies, progress in liquid biopsy techniques, the creation of targeted drug delivery systems, advancements in 3D bioprinting for liver regeneration, the adoption of wearable health monitoring devices, and innovations in nanotechnology-based therapies.

The growing emphasis on precision and personalized medicine is expected to drive the expansion of the acute-on-chronic liver failure (ACLF) market in the coming years. Precision and personalized medicine involve tailoring treatments to individual patients based on genetic, environmental, and lifestyle factors to enhance outcomes and improve care. The increasing use of these approaches is attributed to advancements in genomics, the growing availability of biomarker-based diagnostics, improved data analytics technologies, and the rising demand for more targeted and effective therapies. In the context of ACLF, precision and personalized medicine enable customized treatments based on a patient’s genetic profile, disease severity, and biomarker insights, leading to targeted therapies that improve outcomes and reduce the risk of multi-organ failure. For example, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a notable increase from the 12 approved in 2022. As a result, the increasing focus on precision and personalized medicine is significantly contributing to the growth of the ACLF market.

Leading companies in the ACLF market are prioritizing clinical trials to develop innovative therapeutics, regenerative medicine approaches, and targeted drug therapies aimed at enhancing patient survival rates. Clinical trials play a vital role in validating new treatment protocols, artificial liver support systems, and immunomodulatory therapies to improve disease management and lower mortality rates. For instance, in September 2024, A-TANGO, a Spain-based EU Horizon-funded project, announced plans to conduct the "G-TAK trial" across multiple liver centers in the UK. This trial is designed to assist critically ill patients suffering from alcoholic hepatitis and ACLF. G-TAK is a combinatorial therapy that includes a toll-like receptor 4 antagonist (TAK242) to reduce inflammation, combined with granulocyte colony-stimulating factor (G-CSF, TRL9) to promote hepatocyte proliferation, thereby offering a potential treatment for ACLF.

In September 2022, Genfit, a France-based late-stage biopharmaceutical company, acquired Versantis for $116 million. This acquisition reinforces Genfit’s position in the ACLF market by incorporating a clinically advanced asset with promising Phase Ib and preclinical data, expanding its liver disease pipeline, and utilizing Versantis' expertise to accelerate research and development efforts. Versantis, a Switzerland-based clinical-stage biotechnology company, focuses on addressing the growing unmet medical needs in liver diseases, including ACLF.

Major players in the acute on chronic liver failure (aclf) market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca plc, Abbott Laboratories, GSK plc, Eli Lilly and Company, Gilead Sciences Inc, Novo Nordisk A/S, Astellas Pharma Inc., CSL Behring, Grifols S.A., Lupin Pharmaceutical Limited, Ferring Pharmaceuticals, Shire plc, Gyre Therapeutics Inc., Dr. Falk Pharma GmbH, Genfit, eGenesis Inc., Conatus Pharmaceuticals Inc., Cellaion SA, Rheacell GmbH & Co. KG, Martin Pharmaceuticals Inc.

North America was the largest region in the acute on chronic liver failure (ACLF) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute on chronic liver failure (ACLF) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute on chronic liver failure (ACLF) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Acute on chronic liver failure (ACLF) is a critical condition marked by acute hepatic decompensation in individuals with underlying chronic liver disease. This decline triggers widespread inflammation, leading to the progressive failure of multiple organs. The condition carries a high mortality risk, necessitating quick diagnosis and aggressive medical intervention.

Treatment options for acute on chronic liver failure (ACLF) primarily consist of pharmacological and supportive care. Pharmacological treatments involve the administration of drugs such as antibiotics, vasopressors, corticosteroids, albumin therapy, and liver-specific medications to manage infections, reduce inflammation, support organ function, and stabilize the patient in preparation for possible liver transplantation. These treatments can be delivered through oral or intravenous (IV) routes, and are provided in settings such as hospitals, ambulatory surgical centers, and specialty clinics.

The acute on chronic liver failure (ACLF) market research report is one of a series of new reports that provides acute on chronic liver failure (ACLF) market statistics, including acute on chronic liver failure (ACLF) industry global market size, regional shares, competitors with an acute on chronic liver failure (ACLF) market share, detailed acute on chronic liver failure (ACLF) market segments, market trends and opportunities, and any further data you may need to thrive in the acute on chronic liver failure (ACLF) industry. This acute on chronic liver failure (ACLF) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute on chronic liver failure (ACLF) market consists of revenues earned by entities by providing services such as diagnostic evaluations, intensive care management, liver function monitoring, hemodialysis, extracorporeal liver support therapies, nutritional support, palliative care and liver transplantation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute on chronic liver failure (ACLF) market also includes sales of diagnostic tools and liver support devices aimed at managing disease progression and improving patient outcomes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.